Back to top
more

Amarin (AMRN)

(Real Time Quote from BATS)

$0.90 USD

0.90
311,876

+0.02 (2.62%)

Updated Apr 30, 2024 11:49 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (79 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Deciphera's (DCPH) Q3 Loss Narrows, Qinlock Drives Revenues

by Zacks Equity Research

Deciphera (DCPH) reports a narrower-than-expected loss for the third quarter of 2022 while revenues beat estimates. Qinlock drives year-over-year sales.

    Editas' (EDIT) Q3 Earnings Beat Estimates, Pipeline in Focus

    by Zacks Equity Research

    Editas (EDIT) reports a narrower-than-expected loss for the third quarter of 2022. Focus remains on the lead candidate, EDIT-101, as well as other pipeline candidates.

    Acadia's (ACAD) Q3 Loss Narrower Than Expected, Revenues Miss

    by Zacks Equity Research

    Acadia (ACAD) reports a narrower-than-expected loss in the third quarter of 2022 while revenues fall shy of estimates. Tightens guidance for Nuplazid.

    Horizon's (HZNP) Q3 Earnings & Revenues Surpass Estimates

    by Zacks Equity Research

    Horizon's (HZNP) earnings and revenues beat estimates in the third quarter of 2022. The company raises net sales guidance for 2022. Shares up.

    Amarin (AMRN) Q3 Earnings Beat, Sales Hurt by Vascepa Generics

    by Zacks Equity Research

    Amarin's (AMRN) Vascepa sales decline year over year amid rising generic competition and the restructuring initiatives in the third quarter. The stock witnesses a decline on Oct 27.

    Amarin (AMRN) Q2 Earnings & Sales Hurt by Vazkepa Generics

    by Zacks Equity Research

    Amarin's (AMRN) Vazkepa sales decline year over year amid rising generic competition and COVID-related disruptions during the second quarter. The company's stock witnesses a decline on Aug 3.

    Eli Lilly (LLY) to Report Q2 Earnings: What's in the Cards?

    by Zacks Equity Research

    Higher demand for its key drugs is likely to have offset generic competition for several other drugs and may have boosted Lilly's (LLY) second-quarter sales.

    Amgen (AMGN) to Report Q2 Earnings: What's in the Cards?

    by Zacks Equity Research

    Volume growth from Amgen's (AMGN) key drugs like Prolia, Xgeva, Repatha, and others is expected to have been partially offset by biosimilar/generic competition for mature drugs.

    New Strong Sell Stocks for May 13th

    by Zacks Equity Research

    DDD, AMRN, and BDX have been added to the Zacks Rank #5 (Strong Sell) List on May 13, 2022.

    Amarin (AMRN) Q1 Earnings & Sales Hurt by Vascepa Generics

    by Zacks Equity Research

    Amarin's (AMRN) Vascepa sales decline year over year amid rising generic competition and COVID-related disruptions during the first quarter. The company's stock falls significantly on May 4.

    Amarin (AMRN) Q4 Earnings Top, Sales Hurt by Vascepa Generics

    by Zacks Equity Research

    Amarin's (AMRN) Vascepa sales decline amid rising generic competition and COVID-19 related disruptions during the fourth quarter. The company's stock falls on Mar 1, following the earnings release.

    Amarin (AMRN) is a Top-Ranked Growth Stock: Should You Buy?

    by Zacks Equity Research

    Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

    Why Amarin (AMRN) is a Top Momentum Stock for the Long-Term

    by Zacks Equity Research

    Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

    Is the Options Market Predicting a Spike in Amarin (AMRN) Stock?

    by Zacks Equity Research

    Investors need to pay close attention to Amarin (AMRN) stock based on the movements in the options market lately.

    Amarin (AMRN) Q3 Earnings Top, Vascepa Sales Decline Y/Y

    by Zacks Equity Research

    Amarin's (AMRN) reports lower sales volume for its drug, Vascepa, in the United States during the third quarter. The company's stock falls in pre-market trading.

    All You Need to Know About Amarin (AMRN) Rating Upgrade to Strong Buy

    by Zacks Equity Research

    Amarin (AMRN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

    Amarin (AMRN) Q2 Earnings Top, Vascepa Strong Despite Generics

    by Zacks Equity Research

    Amarin's (AMRN) Vascepa sales benefit from increased demand in the United States during the second quarter. The drug retains majority market share in its segment amid rising generic competition. Stock up.

    What's in the Cards for Amarin (AMRN) This Earnings Season?

    by Zacks Equity Research

    Amarin's (AMRN) second-quarter results are likely to reflect recovery in Vascepa sales amid potential recovery in COVID-19 related disruptions.

    Amarin (AMRN) Q1 Earnings Top, Vascepa Sales Hit by COVID-19

    by Zacks Equity Research

    Amarin's (AMRN) Vascepa sales get hit by COVID-19 and by severe winter storms and power outages in various areas of the United States. Its cost management plan boost the bottom line. Stock up.

    Amarin (AMRN) Q4 Earnings & Revenues Top, Vascepa Sales Solid

    by Zacks Equity Research

    Amarin's (AMRN) revenue growth in the fourth quarter is attributable to continued demand for its cardiovascular drug, Vascepa.

    Amarin (AMRN) Surges: Stock Moves 9% Higher

    by Zacks Equity Research

    Amarin (AMRN) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.

      Is the Options Market Predicting a Spike in Amarin (AMRN) Stock?

      by Zacks Equity Research

      Investors need to pay close attention to Amarin (AMRN) stock based on the movements in the options market lately.

      Amarin's (AMRN) Q3 Earnings Lag, Sales In Line, Stock Down

      by Zacks Equity Research

      Amarin's (AMRN) revenue growth in the third quarter is attributable to continued demand for its cardiovascular drug, Vascepa. Generic competition for Vascepa seems imminent.

      Are Options Traders Betting on a Big Move in Amarin (AMRN) Stock?

      by Zacks Equity Research

      Investors need to pay close attention to Amarin (AMRN) stock based on the movements in the options market lately.

      Biotech Stock Roundup: GILD Submits BLA, ALBO Gains on Study Data & More

      by Zacks Equity Research

      The biotech sector remains in focus with regulatory and other pipeline updates.